换一批Structure-guided optimization of a novel class of ASK1 inhibitors with increased sp<sup>3</sup> character and an exquisite selectivity profile.
第一作者：
Simone V,Bigi-Botterill
第一单位：
Medicinal Chemistry & In Vitro Pharmacology, Gastroenterology Drug Discovery Unit, Takeda Research in California, 9625 Towne Centre Drive, San Diego, CA 92121, United States. Electronic address: simone.bigi@takeda.com.
作者：
医学主题词
动物(Animals);结合部位(Binding Sites);催化域(Catalytic Domain);结晶学, X线(Crystallography, X-Ray);药物设计(Drug Design);人类(Humans);咪唑类(Imidazoles);半数抑制浓度(Inhibitory Concentration 50);MAP激酶激酶激酶5(MAP Kinase Kinase Kinase 5);小鼠(Mice);分子动力学模拟(Molecular Dynamics Simulation);心肌再灌注损伤(Myocardial Reperfusion Injury);蛋白激酶抑制剂(Protein Kinase Inhibitors)
DOI
10.1016/j.bmcl.2020.127405
PMID
32738982
发布时间
2021-06-08
- 浏览2
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
